Cellectis SA (NAS:CLLS)

$ 2.25 -0.15 (-6.25%) Market Cap: 228.13 Mil Enterprise Value: 46.61 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 54/100

Q1 2024 Cellectis SA Earnings Call Transcript
May 29, 2024

$2.72 (-2.16%)

Earnings
Q3 2023 Cellectis SA Earnings Call Transcript
Nov 07, 2023

$2.39 (-13.41%)

Earnings
Cellectis SA at Jefferies Cell & Genetic Medicine Summit Transcript
Sep 26, 2023
Q2 2023 Cellectis SA Earnings Call Transcript
Aug 04, 2023

$1.85 (-5.13%)

Earnings
Cellectis SA at Goldman Sachs Healthcare Conference Transcript
Jun 15, 2023
Q1 2023 Cellectis SA Earnings Call Transcript
May 05, 2023

$1.9 (+1.06%)

Earnings
Cellectis SA at Barclays Global Healthcare Conference Transcript
Mar 14, 2023
Q4 2022 Cellectis SA Earnings Call Transcript
Mar 09, 2023

$2.08 (-3.94%)

Earnings
Cellectis SA Corporate Analyst Meeting (Virtual) Transcript
Dec 13, 2022
Q3 2022 Cellectis SA Earnings Call Transcript
Nov 04, 2022

$2.34 (-4.10%)

Earnings
Atara Biotherapeutics Inc, Cellectis SA and 2Seventy Bio Inc at Citi BioPharma Conference- Panel Transcript
Sep 07, 2022
Q2 2022 Cellectis SA Earnings Call Transcript
Aug 05, 2022

$3.46 (+10.90%)

Earnings
Cellectis SA at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022
Cellectis SA at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Q1 2022 Cellectis SA Earnings Call Transcript
May 13, 2022

$3.17 (+3.93%)

Earnings
Cellectis SA at Barclays Global Healthcare Conference Transcript
Mar 17, 2022
Q4 2021 Cellectis SA Earnings Call Transcript
Mar 04, 2022

$3.53 (-6.86%)

Earnings
Cellectis SA at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Nov 15, 2021
Q3 2021 Cellectis SA Earnings Call Transcript
Nov 05, 2021

$12.23 (-0.41%)

Earnings
Cellectis SA at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Cellectis SA Earnings Call Transcript
Aug 06, 2021

$14.28 (+4.16%)

Earnings
Cellectis SA at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021
Q4 2020 Cellectis SA Earnings Call Transcript
Mar 05, 2021

$18.19 (-5.80%)

Earnings
Cellectis SA at Barclays Virtual Gene Editing & Gene Therapy Summit - Presentation Transcript
Nov 16, 2020
Q3 2020 Cellectis SA Earnings Call Transcript
Nov 06, 2020

$17.06 (-5.90%)

Earnings
Cellectis SA at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Q2 2020 Cellectis SA Earnings Call Transcript
Aug 06, 2020

$16.91 (-4.89%)

Earnings
Cellectis SA Chardan Leadership Call Transcript
May 27, 2020
Q1 2020 Cellectis SA Earnings Call Transcript
May 07, 2020

$14.58 (+0.90%)

Earnings
Q4 2019 Cellectis SA Earnings Call Transcript
Mar 05, 2020

$15.74 (-1.69%)

Earnings
Q3 2019 Cellectis SA Earnings Call Transcript
Nov 07, 2019

$12.77 (+0.63%)

Earnings
Cellectis SA at Citi Biotech Conference Transcript
Sep 04, 2019
Cellectis SA at Goldman Sachs Global Healthcare Conference Transcript
Jun 13, 2019
Cellectis SA at Barclays Global Healthcare Conference Transcript
Mar 13, 2019
Q4 2018 Cellectis SA Earnings Call Transcript
Mar 12, 2019

$18.71 (+1.91%)

Earnings

Cellectis SA at Goldman Sachs Healthcare Conference Transcript

Jun 15, 2023 / 05:00PM GMT

Release Date Price: $2.04 (+2.51%)

Transcript

Anoumid Vaziri

Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, everyone. I'm Anoumid Vaziri. And I'm joined on stage with Bing Wang, CFO of Cellectis. Bing, thank you for being here with us today.

Bing C. Wang

Cellectis S.A. - CFO

Thank you for inviting me.

Questions & Answers

Anoumid Vaziri

Goldman Sachs Group, Inc., Research Division - Research Analyst

And so to start, Cellectis is a clinical stage biotech company using its TALENs gene editing platform to develop allogeneic cell therapies. Could you provide an overview of your portfolio, both on the partnered and the wholly-owned assets and then discuss how you're differentiated as a company in the cell therapy space?

Bing C. Wang

Cellectis S.A. - CFO

Great. Thank you very much. So I would say we would put our portfolio in 3 buckets. The first is our wholly-owned clinical asset. So we have UCART22 going after ALL. We have UCART123 going after AML. We can go into that in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.